Yes, time will tell. Monday's blog should, at
Post# of 30028
Monday's blog should, at the very least, ease some tension. There were no indicators flagging investors of the share count doubling.
There was no need for cash to dilute. As of now there is plenty there and readily available if necessary.
The logical choice is, as has been pointed out earlier, splitting the diagnostics and the therapeutics into two different entities/divisions. The company's reasoning would be obvious to any serious investor in Amarantus to take this course, but to bashers, it's their field day.
To be honest, I considered unloading some of my position when the news hit, but the more I think it through, the more I refrain from pulling the trigger on this.
Have a great weekend all....